JO
NXTC icon

John Overdeck’s NextCure NXTC Stock Holding History

John Overdeck’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,821
Closed -$47.7K – 3135
2022
Q4 		$47.7K Sell
2,821
-2,431
-46% -$55.9K ﹤0.01% 2596
2022
Q3 		$173K Buy
5,252
+3,811
+264% +$194K ﹤0.01% 2139
2022
Q2 		$81K Buy
+1,441
New +$75.3K ﹤0.01% 2292
2022
Q1 		– Sell
-1,176
Closed -$85K – 3821
2021
Q4 		$85K Sell
1,176
-4,834
-80% -$404K ﹤0.01% 4087
2021
Q3 		$486K Buy
6,010
+1,236
+26% +$108K ﹤0.01% 3291
2021
Q2 		$460K Sell
4,774
-1,847
-28% -$189K ﹤0.01% 3179
2021
Q1 		$795K Buy
+6,621
New +$959K ﹤0.01% 2525
2020
Q4 		– Sell
-15,003
Closed -$1.58M – 3633
2020
Q3 		$1.58M Buy
15,003
+4,854
+48% +$597K 0.01% 1444
2020
Q2 		$2.61M Buy
+10,149
New +$3.86M 0.01% 966
2020
Q1 		– Sell
-1,588
Closed -$1.07M – 3628
2019
Q4 		$1.07M Buy
+1,588
New +$797K ﹤0.01% 2116

Other funds holding NXTC

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

John Overdeck's NXTC Position: Q1 2023 in Review

John Overdeck sold out of NextCure (NXTC) in Q1 2023, closing a stake of 2,821 shares — an estimated $47.7K sold.

John Overdeck first reported a position in NXTC in Q4 2019 and held it in 10 quarters. The position peaked at $2.61M in Q2 2020. 43 funds tracked by Wall St. Rank hold NXTC as of Q1 2023.

  • John Overdeck reported no remaining NextCure position as of Q1 2023 after selling out during the quarter.
  • John Overdeck sold 2,821 NextCure shares in Q1 2023, an estimated $47.7K.
  • John Overdeck first reported a position in NextCure in Q4 2019 and held it in 10 quarters.
  • John Overdeck's NextCure position peaked at $2.61M in Q2 2020.
  • 43 funds tracked by Wall St. Rank held NextCure as of Q1 2023.

Based on Two Sigma Investments's 13F filing for Q1 2023, filed 15 May 2023.